Premium
Treatment of Drug‐Tolerant Choriocarcinoma in Combination with Bleomycin, Cisplatin and VP16‐213 (Etoposide)
Author(s) -
Yamamoto Takara,
Shiroshita Kohe,
Tsuji Masamichi,
Okada Hiroji
Publication year - 1986
Publication title -
asia‐oceania journal of obstetrics and gynaecology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.597
H-Index - 50
eISSN - 1447-0756
pISSN - 0389-2328
DOI - 10.1111/j.1447-0756.1986.tb00186.x
Subject(s) - etoposide , bleomycin , cisplatin , medicine , refractory (planetary science) , choriocarcinoma , hysterectomy , chemotherapy , surgery , physics , astrobiology
A 38‐year‐old patient with choriocarcinoma who was tolerant to MTX and Act‐D and highly refractory to MECA therapy after hysterectomy and bilateral oophorec‐tomy was treated with 4 courses of BCE therapy. One course of BCE therapy consisted of bleomycin (Bleo Inj.®, Nihon Kayaku Co., Ltd., Tokyo Japan. Day 1–5: 5 mg i.v. infusion/day); cisplatin (Briplatin®, Bristol‐Myers Co., Ltd., Tokyo, Japan. Day 1; 50 mg i.v. infusion/m 2 ); and VP16‐213, (Etoposide, Day 1–5: 100 mg i.v. infusion/m 2 /day). This treatment was successful in achieving complete remission.